Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-06-16

Clinical Trial Results: Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab as treatment for Stage IIB-IIC melanoma that can be surgically removed; results completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED | Results posted: 2026-06-16